公开(公告)号：EP0848721A4

公开(公告)日：2000-12-27

申请号：EP96929937

申请日：1996-09-06

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  TOWELL J ANDREW ,  HARNESS JAMES R

IPC: C12N15/09 ,  B01J19/00 ,  B01L3/00 ,  B01L7/00 ,  C08F2/00 ,  C12M1/00 ,  C40B60/14

CPC classification number: B01L3/50851 ,  B01J19/0046 ,  B01J2219/00283 ,  B01J2219/00308 ,  B01J2219/0031 ,  B01J2219/00335 ,  B01J2219/00373 ,  B01J2219/00484 ,  B01J2219/00495 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01L3/50853 ,  B01L7/52 ,  C40B60/14

Abstract: A method and device (2) for the simultaneous production of chemical compounds in an array which is capable of providing a very broad range of reaction environments including reaction temperatures of -40 °C to 150 °C, reflux condensation, and a selective gas environment. The invention also allows the addition of several reagents (4) during the course of the production process. The device (2) is comprised of a number of different block sections (6, 24, 18) which are fastened together to provide the required reaction environment.

公开(公告)号：PL348812A1

公开(公告)日：2002-06-17

申请号：PL34881299

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K20060101 ,  A61K9/00 ,  A61K9/12 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.

公开(公告)号：AU706448B2

公开(公告)日：1999-06-17

申请号：AU6395496

申请日：1996-06-25

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  SHAOPEI CAI ,  KEELER ERIC L

IPC: A61K31/535 ,  A61K31/55 ,  A61P31/00 ,  C07D487/04 ,  C07D498/04 ,  C07D498/00 ,  C07D403/00 ,  C07D235/02 ,  C07D223/16

Abstract: Methods, compounds and compositions are provided for inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial and clostridium infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): (II) wherein R1 is hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocycle, substituted heterocycle and heterocyclicalkyl; X is oxygen, sulfur or NK2, where R2 is hydrogen, loweralkyl, aryl, cycloalkyl, heterocycle, substituted heterocycle, heterocyclicalkyl, COR3 or SO2R4CONR4R5, where R4 and R5 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alkoxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; n is 1, 2 or 3; Y and Z are independently selected CH2, CO, CR4R5 or NR4, where R4 and R5 are as defined above; provided that when n is 2 or 3, the compounds of formula II can be additionally substituted as follows: (IIa) (IIb) wherein R6, R7, R8 and R9 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alkoxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis and Clostridium difficile.

公开(公告)号：BR9916296A

公开(公告)日：2004-06-29

申请号：BR9916296

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K9/12 ,  A61K20060101 ,  A61K9/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.

公开(公告)号：HU0105226A2

公开(公告)日：2002-04-29

申请号：HU0105226

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  MONTGOMERY ALAN B

IPC: A61K20060101 ,  A61K9/12 ,  A61K9/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: A tal lm ny t rgy t egy, a súlyos krónikus bronchitis (bronchiectasia)kezelésére szolg ló elj r s képezi, mely egy koncentr lt antibiotikum-készítményt alkalmaz, mely az antibiotikumot a tüdő alveolusokat istartalmazó endobronchi lis terébe juttatja egy aeroszol vagy egy szraz por alakj ban, melynek t"meg tlagos tmérője túlnyomórészt 1 és 5mikron k"z"tt van. Az elj r s sor n az antibiotikumot olyan koncentrcióban alkalmazz k, mely 1-10000-szer magasabb, mint a célszervbenmért minim lis inhibitor-koncentr ció. Előny"sen, az elj r s sor n azaeroszol vagy sz raz por alakban lévő tobramycint endobronchi lisanjuttatj k be a pseudomonas-fertőzések kezelésére a súlyos krónikusbronchitisben (bronchiectasi ban) szenvedő betegeknél. Ó

公开(公告)号：CA2355775A1

公开(公告)日：2000-06-22

申请号：CA2355775

申请日：1999-12-17

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  BAKER WILLIAM R

IPC: A61K9/12 ,  A61K20060101 ,  A61K9/00 ,  A61K9/14 ,  A61K9/72 ,  A61K31/70 ,  A61K31/7036 ,  A61M11/00 ,  A61M13/00 ,  A61P11/00 ,  A61P11/08 ,  A61P31/04

Abstract: A method for treatment of severe chronic bronchitis (bronchiectasis) using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space including alveoli in an aerosol or dry powde r having mass medium diameter predominately between 1 to 5 microns. The method comprises administration of the antibiotic in a concentration one to ten thousand times higher than the minimal inhibitory concentration of the targe t organism. Preferably, the method comprises endobronchial administration of aerosol or dry powder tobramycin to treat pseudomonal infections in severe chronic bronchitis (bronchiectasis) patients.

公开(公告)号：AU1210095A

公开(公告)日：1995-06-06

申请号：AU1210095

申请日：1994-11-17

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  MITSCHER LESTER A

IPC: C07D471/14 ,  C07D487/04 ,  C07D487/14 ,  C07D495/14 ,  C07D513/14 ,  A61K31/38 ,  A61K31/505 ,  A61K31/53 ,  A61K31/495 ,  C07D487/22 ,  C07D473/22

Abstract: Methods, compounds and compositions are provided form inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic mycobacterial infections in vivo using indolo[2,1-b]quinazoline-6,12-dione compounds of the formula (I): are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, and may be used alone, or in combination with other anti-Mycobacterium tuberculosis agents, such as isoniazid, rifampin, pyrazinamide, rifabutin, streptomycin and ciprofloxacin, to provide new agents for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDRTB).

公开(公告)号：AU6916396A

公开(公告)日：1997-03-27

申请号：AU6916396

申请日：1996-09-06

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  TOWELL J ANDREW ,  HARNESS JAMES R

IPC: C12N15/09 ,  B01J19/00 ,  B01L3/00 ,  B01L7/00 ,  C08F2/00 ,  C12M1/00 ,  C40B60/14 ,  C12C1/00 ,  G01N21/00

公开(公告)号：AU6395496A

公开(公告)日：1997-01-30

申请号：AU6395496

申请日：1996-06-25

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  SHAOPEI CAI ,  KEELER ERIC L

IPC: A61K31/535 ,  A61K31/55 ,  A61P31/00 ,  C07D487/04 ,  C07D498/04 ,  C07D498/00 ,  C07D403/00 ,  C07D235/02 ,  C07D223/16

Abstract: Methods, compounds and compositions are provided for inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial and clostridium infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): (II) wherein R1 is hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocycle, substituted heterocycle and heterocyclicalkyl; X is oxygen, sulfur or NK2, where R2 is hydrogen, loweralkyl, aryl, cycloalkyl, heterocycle, substituted heterocycle, heterocyclicalkyl, COR3 or SO2R4CONR4R5, where R4 and R5 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alkoxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; n is 1, 2 or 3; Y and Z are independently selected CH2, CO, CR4R5 or NR4, where R4 and R5 are as defined above; provided that when n is 2 or 3, the compounds of formula II can be additionally substituted as follows: (IIa) (IIb) wherein R6, R7, R8 and R9 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alkoxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; and the pharmaceutically acceptable salts thereof. The methods, compounds and compositons are particularly useful for inhibiting the growth of Mycobacterium tuberculosis and Clostridium difficile.

公开(公告)号：CA2225822C

公开(公告)日：2010-02-16

申请号：CA2225822

申请日：1996-06-25

Applicant: PATHOGENESIS CORP

Inventor： BAKER WILLIAM R ,  SHAOPEI CAI ,  KEELER ERIC L

IPC: C07D498/04 ,  A61K31/505 ,  A61K31/535 ,  A61K31/54 ,  A61K31/55 ,  A61P31/00 ,  C07D487/04 ,  C07D513/04

Abstract: Methods, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial, Clostridium, Cryptosporidium and Helicobacter infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): (see formula II) The methods, compounds and compositions are particularly useful for inhibiting the growth of Mycobacterium tuberculosis, Clostridium difficile, Cryptosporidium parvum, and Helicobacter pylori, and may be used alone, or in combination with other antimicrobial agents.